References
- Creutzig U, Ritter J, Zimmermann M, et al A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 1998;103:100–109.
- Bradstock KF, Matthews JP, Lowenthal RM, et al A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005;105:481–488.
- Preisler HD, Anderson K, Rai K, et al The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Br J Haematol 1989;71:189–194.
- Geller RB. Post-remission therapy of acute myelocytic leukemia in adults: curability breeds controversy. Leukemia 1992;6:915–925.
- Frassoni F, Labopin M, Gluckman E, et al Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1994;8:924–928.
- Dann EJ, Gillis S, Rowe JM. Late relapse following autologous bone marrow transplantation for acute myelogenous leukemia: case report and review of the literature. Leukemia 1995;9:1072–1074.
- Schiffer CA, Dodge R, Larson RA. Long-term follow-up of Cancer and Leukemia Group B studies in acute myeloid leukemia. Cancer 1997;80:2210–2214.
- Medeiros BC, Minden MD, Schuh AC, et al Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years). Leuk Lymphoma 2007;48:65–71.
- Ustün C, Kalla A, Bollag RJ, Manaloo E, Kulharya A, Jillella A. Relapsed acute myelogenous leukemia occurring after 18 years with recurrent novel chromosomal abnormality t(18;22) (q23;q11.2). Cancer Genet Cytogenet 2007;177:135–138.
- Kikushige Y, Takase K, Miyamoto T, et al Late relapse of acute myelogenous leukemia followed by Epstein-Barr virus-associated lymphoproliferative disease 11 years after allogeneic bone marrow transplantation. Int J Hematol 2006;84:441–444.
- Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 1988;6:232–238.
- Cheson BD, Bennett JM, Kopecky KJ, et al Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
- Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002;43:1715–1727.
- Craddock C, Tauro S, Moss P, Grimwade D. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005;129:18–34.
- Weltermann A, Fonatsch C, Haas OA, et al Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 2004;18:293–302.
- Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99:1909–1912.
- Konrad M, Metzler M, Panzer S, et al Late relapses evolve from slow responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone. Blood 2003;101:3635–3640.